Medicaid drug rebate bill (HR 2890)
Executive Summary
Passes House by voice vote Sept. 22. The measure would amend OBRA '90 by exempting discount prices offered by drug manufacturers to the Veterans Affairs Department, Defense Department, PHS-funded clinics and other government purchasers from Medicaid rebate calculations. It also would guarantee that such purchasers can buy pharmaceuticals at prices at least as low as those obtained by Medicaid, and ensure that prices to V-A are at least 24% lower than those paid by wholesalers for products resold to retail pharmacies. In addition, the bill would raise minimum rebates for Medicaid from 15% to 15.7% in 1993, 15.4% in 1994, 15.2% in 1995 and 15.1% in 1996.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth